GP9 Human

Glycoprotein-9 Human Recombinant
Cat. No.
BT13560
Source
Escherichia Coli.
Synonyms
Platelet glycoprotein IX, GP-IX, GPIX, Glycoprotein 9, CD42a, Glycoprotein IX (Platelet).
Appearance
Sterile Filtered colorless solution.
Purity
Greater than 90.0% as determined by SDS-PAGE.
Usage
THE BioTek's products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
Shipped with Ice Packs
In Stock
Quick Inquiry

Description

GP9 Human Recombinant produced in E.coli is a single, non-glycosylated polypeptide chain containing 154 amino acids (17-147) and having a molecular mass of 16.8kDa. GP9 is fused to a 23 amino acid His-tag at N-terminus & purified by proprietary chromatographic techniques.

Product Specs

Introduction
Glycoprotein-9 (GP9) is a small membrane glycoprotein present on the surface of human platelets. It forms a stable complex with glycoprotein Ib, another platelet surface glycoprotein, in a one-to-one stoichiometry. This GP9-GP Ib complex acts as a receptor for the von Willebrand factor. The complete receptor complex comprises the non-covalently associated alpha and beta subunits of GP Ib, GP9, and platelet glycoprotein V. Genetic defects in the GP9 gene lead to Bernard-Soulier syndrome, also known as giant platelet disease. This disorder is characterized by abnormally large platelets and a predisposition to bleeding.
Description
Recombinant human GP9, expressed in E. coli, is a single, non-glycosylated polypeptide chain consisting of 154 amino acids (residues 17-147) with a molecular weight of 16.8 kDa. This protein is engineered with a 23 amino acid His-tag at its N-terminus and is purified using proprietary chromatographic methods.
Physical Appearance
A clear, colorless solution that has been sterilized by filtration.
Formulation
The GP9 protein solution has a concentration of 1 mg/ml and is formulated in a buffer containing 20 mM Tris-HCl (pH 8.0), 2 M urea, and 10% glycerol.
Stability
For short-term storage (up to 2-4 weeks), the product can be stored at 4°C. For extended storage, it is recommended to freeze the product at -20°C. The addition of a carrier protein such as HSA or BSA (0.1%) is advised for long-term storage. Repeated freezing and thawing should be avoided.
Purity
The purity of the GP9 protein is determined to be greater than 90.0% by SDS-PAGE analysis.
Synonyms
Platelet glycoprotein IX, GP-IX, GPIX, Glycoprotein 9, CD42a, Glycoprotein IX (Platelet).
Source
Escherichia Coli.
Amino Acid Sequence
MGSSHHHHHH SSGLVPRGSH MGSTKDCPSP CTCRALETMG LWVDCRGHGL TALPALPART RHLLLANNSL QSVPPGAFDH LPQLQTLDVT QNPWHCDCSL TYLRLWLEDR TPEALLQVRC ASPSLAAHGP LGRLTGYQLG SCGWQLQASW VRPG.

Product Science Overview

Introduction

Glycoprotein-9 (GP9), also known as Galectin-9 (Gal-9), is a member of the galectin family of proteins. These proteins are characterized by their ability to bind to specific carbohydrate structures on glycoproteins and glycolipids. Galectin-9 is known for its diverse roles in various physiological and pathological processes, including immune response modulation, cell adhesion, and apoptosis.

Structure and Function

Galectin-9 is a tandem-repeat type galectin, meaning it has two carbohydrate recognition domains (CRDs) connected by a linker peptide. This structure allows Galectin-9 to cross-link glycoproteins on the cell surface, leading to various cellular responses. The protein is involved in several key functions:

  • Immune Regulation: Galectin-9 plays a crucial role in modulating immune responses. It can induce apoptosis in certain immune cells, such as T cells, and has been shown to suppress autoimmune responses.
  • Cell Adhesion and Migration: By binding to glycoproteins on the cell surface, Galectin-9 can influence cell adhesion and migration, which are critical processes in tissue repair and cancer metastasis.
  • Platelet Activation: Recent studies have identified Galectin-9 as a novel ligand for platelet glycoprotein VI (GPVI) and C-type lectin-like receptor 2 (CLEC-2). This interaction leads to platelet activation, which is essential for blood clotting and wound healing .
Recombinant Production

Human recombinant Galectin-9 is produced using recombinant DNA technology. This involves inserting the gene encoding Galectin-9 into a suitable expression system, such as bacteria or mammalian cells, to produce the protein in large quantities. The recombinant protein is then purified for use in research and therapeutic applications.

Applications in Research and Medicine

Galectin-9 has been extensively studied for its potential therapeutic applications:

  • Cancer Therapy: Due to its role in modulating immune responses and influencing cell adhesion, Galectin-9 is being investigated as a potential therapeutic target in cancer treatment. It may help in enhancing anti-tumor immune responses and inhibiting metastasis.
  • Autoimmune Diseases: Galectin-9’s ability to suppress autoimmune responses makes it a promising candidate for treating autoimmune diseases such as multiple sclerosis and rheumatoid arthritis.
  • Infectious Diseases: Research has shown that Galectin-9 can inhibit the replication of certain viruses, including HIV, making it a potential antiviral agent.

Quick Inquiry

Personal Email Detected
Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *

Category

Service

THE BIOTEK
THE BioTek is a global biotech company offering highly purified proteins for research in cancer, apoptosis, development, endocrinology, immunology, neuroscience, proteases, and stem cells.
  • Contact
  • Address: 1925 E Maple Ave, El Segundo, CA 90245 United States
  • Phone : +1 201-285-7826
  • Email : info@thebiotek.com
  • Hours : Mon.-Fri. 9:00 AM - 5:00 PM
© Copyright 2024 Thebiotek. All Rights Reserved.